Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maher Albitar

Showing results (161-170 of 214) with videos related to

Pageof 22
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignanciesKaren W L Yee, Zhihong Zeng, Marina Konopleva, et al.
Blood|October 16, 2009
Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective studyHuei-Ting Tsai, Neil E Caporaso, Robert A Kyle, et al.
Hematology/Oncology and Stem Cell Therapy|October 26, 2012
The t(9;11) confers good prognosis in AML patients treated with stem cell transplantation as compared to non-t(9;11) and other adverse-risk abnormalitiesClaudia Ulrike Walter, Fahad Al Mohareb, Naeem Chaudhri, et al.
Cancer|March 26, 2004
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemiaFrancis J Giles, Martin S Tallman, Guillermo Garcia-Manero, et al.
Leukemia Research|March 21, 2006
Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's diseaseMaher Albitar, Julie M Vose, Marcella M Johnson, et al.
Leukemia Research|June 15, 2007
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasiaFrancis J Giles, Alan F List, Michael Carroll, et al.
British Journal of Haematology|October 3, 2002
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survivalFrancis J Giles, Hagop M Kantarjian, B Nebiyou Bekele, et al.
Blood|August 1, 2002
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemiaAlessandra Ferrajoli, Michael J Keating, Taghi Manshouri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myelomaMaurizio Zangari, Elias Anaissie, Alison Stopeck, et al.
Leukemia Research|May 4, 2004
Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphomaFrancis J Giles, Julie M Vose, Kim-Anh Do, et al.
Pageof 22

Showing results (161-170 of 214) with videos related to

Sort By:
Pageof 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignanciesKaren W L Yee, Zhihong Zeng, Marina Konopleva, et al.
Blood|October 16, 2009
Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective studyHuei-Ting Tsai, Neil E Caporaso, Robert A Kyle, et al.
Hematology/Oncology and Stem Cell Therapy|October 26, 2012
The t(9;11) confers good prognosis in AML patients treated with stem cell transplantation as compared to non-t(9;11) and other adverse-risk abnormalitiesClaudia Ulrike Walter, Fahad Al Mohareb, Naeem Chaudhri, et al.
Cancer|March 26, 2004
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemiaFrancis J Giles, Martin S Tallman, Guillermo Garcia-Manero, et al.
Leukemia Research|March 21, 2006
Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's diseaseMaher Albitar, Julie M Vose, Marcella M Johnson, et al.
Leukemia Research|June 15, 2007
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasiaFrancis J Giles, Alan F List, Michael Carroll, et al.
British Journal of Haematology|October 3, 2002
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survivalFrancis J Giles, Hagop M Kantarjian, B Nebiyou Bekele, et al.
Blood|August 1, 2002
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemiaAlessandra Ferrajoli, Michael J Keating, Taghi Manshouri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myelomaMaurizio Zangari, Elias Anaissie, Alison Stopeck, et al.
Leukemia Research|May 4, 2004
Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphomaFrancis J Giles, Julie M Vose, Kim-Anh Do, et al.
Pageof 22